{"gene":"GCG","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":1986,"finding":"GLP-1 and GLP-2 (predicted products of the proglucagon/GCG gene) are secreted separately from pig small intestine L cells (glicentin-producing cells) in parallel with intestinal glicentin upon luminal glucose or GRP stimulation, whereas pancreatic GCG expression yields a large peptide containing both GLP-1 and GLP-2 immunoreactivity co-secreted with glucagon upon arginine stimulation.","method":"RIA with specific antisera, reverse-phase HPLC, isolated perfused pig pancreas and ileum","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro/ex vivo secretion assay with HPLC characterization, replicated across two different tissue preparations","pmids":["3530719"],"is_preprint":false},{"year":1999,"finding":"GLP-2 signals through the GLP-2 receptor (a G protein-coupled receptor) to activate cAMP accumulation and PKA-dependent AP-1 transcriptional activity; it also stimulates c-fos, c-jun, junB and zif268 expression and transiently increases p70 S6 kinase, while inhibiting ERK1/2 and reducing serum-stimulated Elk-1 activity. Critically, 8-bromo-cAMP alone did not promote cell proliferation, indicating that GLP-2R mitogenic signaling involves PKA-independent downstream mediators.","method":"Transfected BHK cells expressing rat GLP-2R; cAMP assay, luciferase reporter assays, dominant-negative PKA inhibitor, immunoblotting","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal signaling assays in a defined cell system with dominant-negative controls, single lab","pmids":["10521425"],"is_preprint":false},{"year":2000,"finding":"GLP-2 receptor (GLP-2R) is expressed in enteroendocrine cells of the stomach, small bowel, and colon epithelium in humans and rodents, and also in the hypothalamus, brain stem, and lung, suggesting indirect epithelial action via downstream mediators.","method":"Northern blotting, RT-PCR, immunocytochemistry on rodent and human tissues","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal localization methods in two species, replicated in multiple tissue types","pmids":["10982769"],"is_preprint":false},{"year":2001,"finding":"GLP-2 receptor activation suppresses crypt cell apoptosis through inhibition of caspase-8 and caspase-3 activation and inhibition of PARP cleavage, as demonstrated in heterologous cells transfected with the GLP-2 receptor.","method":"Cells transfected with GLP-2 receptor; caspase-8/-3 activity assays, PARP cleavage by Western blot; murine chemotherapy models","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined cellular mechanism with multiple molecular readouts in transfected cells plus in vivo confirmation, single lab","pmids":["11212269"],"is_preprint":false},{"year":2001,"finding":"Central (intracerebroventricular) GLP-2 inhibits food intake in mice via GLP-2R expressed in multiple extrahypothalamic brain regions; disruption of GLP-1 receptor signaling (pharmacologically or genetically in GLP-1R-/- mice) potentiates the anorectic effect of GLP-2, indicating that GLP-1R signaling modulates CNS GLP-2 action.","method":"ICV injection in wild-type and GLP-1R-/- mice; exendin-(9-39) antagonist; LacZ transgenic reporter driven by GLP-2R promoter; GLP-2R expression mapping","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic and pharmacological epistasis in two independent mouse models, multiple orthogonal methods","pmids":["11262390"],"is_preprint":false},{"year":2002,"finding":"The primary DPP-IV degradation product GLP-2(3-33) binds the GLP-2 receptor with ~7.5% affinity of GLP-2(1-33), stimulates cAMP at ~15% efficacy, and acts as a partial agonist/competitive antagonist at the GLP-2 receptor, attenuating the intestinotrophic effects of GLP-2(1-33) when co-administered at high doses.","method":"Receptor-binding assay and cAMP accumulation in cells expressing transfected human GLP-2R; in vivo intestinal growth assay in mice with co-administration","journal":"Regulatory peptides","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro receptor binding and functional cAMP assay combined with in vivo dose-response, single lab with multiple methods","pmids":["11738243"],"is_preprint":false},{"year":2005,"finding":"GLP-2 stimulates colonic growth via keratinocyte growth factor (KGF) released from subepithelial myofibroblasts that express the GLP-2 receptor; anti-KGF antibody abolishes GLP-2-induced large intestinal growth but not small intestinal growth, establishing KGF as an obligate downstream paracrine mediator in the colon.","method":"Immunohistochemistry and in situ hybridization for GLP-2R on myofibroblasts; double-labeling for alpha-smooth muscle actin and KGF; in vivo GLP-2 ± KGF antibody infusion in mice","journal":"Regulatory peptides","confidence":"High","confidence_rationale":"Tier 2 / Strong — co-localization plus antibody neutralization epistasis in vivo, orthogonal methods, multiple species","pmids":["15544847"],"is_preprint":false},{"year":2006,"finding":"GLP-2R protein co-localizes with serotonin in enteroendocrine cells and with eNOS-expressing/VIP-positive enteric neurons in porcine intestine; GLP-2 infusion dose-dependently stimulates intestinal blood flow and upregulates intestinal eNOS mRNA, protein, and phosphorylation (eNOS-Ser1117), demonstrating that GLP-2 increases mesenteric blood flow via vasoactive neurotransmitters co-localized with GLP-2R.","method":"qRT-PCR on laser-capture microdissected subtissue, FISH, triple immunostaining/confocal microscopy; in vivo GLP-2 infusion in neonatal pigs with superior mesenteric artery blood flow measurement and eNOS quantification","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal localization methods combined with functional vascular endpoint, validated antibody, porcine model","pmids":["16401478"],"is_preprint":false},{"year":2006,"finding":"GLP-2 rapidly activates divergent intracellular signaling pathways in neonatal piglet intestinal epithelial cells: within 1–4 h, GLP-2 phosphorylates PKA, PKB/Akt, ERK1/2, CREB, and c-Fos, suppresses caspase-3 activation, and upregulates Bcl-2 and IAP family members (XIAP, cIAP-2), preceding the trophic morphological changes seen at 48 h.","method":"In vivo GLP-2 infusion in TPN-fed neonatal piglets with intestinal tissue analysis by Western blotting, immunostaining for signaling proteins; BrdU proliferation and TUNEL apoptosis assays at multiple time points","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 2 / Moderate — systematic time-course with multiple orthogonal molecular endpoints in a defined in vivo model, single lab","pmids":["16954336"],"is_preprint":false},{"year":2009,"finding":"ErbB receptor signaling is required for the proliferative and bowel-growth effects of GLP-2: exogenous GLP-2 rapidly induces amphiregulin, epiregulin, and HB-EGF (ErbB ligands) and immediate-early gene expression in the gut in a GLP-2R-dependent manner (absent in Glp2r-/- mice), and these effects and the stimulatory actions on crypt cell proliferation are abolished by the pan-ErbB inhibitor CI-1033 or markedly diminished in hypomorphic Egfr(wa2) mice.","method":"Gene expression profiling, GLP-2 administration in wild-type, Glp2r-/- and Egfr(wa2) mice; pan-ErbB inhibitor CI-1033; metalloproteinase inhibitor; crypt cell proliferation assay","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic (two KO models) and pharmacological epistasis with multiple downstream readouts, single lab with orthogonal approaches","pmids":["19523469"],"is_preprint":false},{"year":2009,"finding":"GLP-2 potentiates L-type voltage-gated Ca2+ channel (VGCC) activity in hippocampal neurons through a PKA-dependent mechanism, and this potentiation partially mediates GLP-2-stimulated glucose uptake by primary hippocampal neurons. GLP-2(1-33) binds specifically to hippocampal neurons with Kd = 0.48 nM.","method":"Whole-cell patch clamp recording of barium currents; PKA inhibitor (PKI(14-22)); nifedipine for L-type Ca2+ channel block; [3H]-2-deoxyglucose uptake; 125I-labeled GLP-2 binding; fluorescent glucose analog imaging","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 1 / Moderate — patch clamp (gold standard for channel function) combined with pharmacological dissection and radioligand binding, single lab with multiple methods","pmids":["19920220"],"is_preprint":false},{"year":2012,"finding":"GLP-2R in POMC neurons suppresses food intake and gastric emptying; GLP-2-mediated anorectic and motility effects require MC4R signaling, as these effects were abolished in MC4R KO mice. Mice lacking Glp2r specifically in POMC neurons showed hyperphagia, accelerated gastric emptying, and late-onset obesity.","method":"Cre-LoxP conditional knockout (POMC-specific Glp2r deletion); ICV GLP-2 infusion; MC4R KO mice; 13C-octanoic acid breath test for gastric emptying; food intake measurement","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional genetic knockout with ICV pharmacology and epistasis via MC4R KO, multiple phenotypic readouts","pmids":["22829581"],"is_preprint":false},{"year":2013,"finding":"Central GLP-2 enhances hepatic insulin sensitivity through PI3K signaling in POMC neurons: GLP-2R activation in POMC neurons initiates GLP-2R–p85α interaction, facilitating PI3K–Akt-dependent FoxO1 nuclear exclusion, modulating membrane excitability, and suppressing hepatic glucose production (HGP). Mice lacking GLP-2R in POMC neurons show glucose intolerance and hepatic insulin resistance.","method":"Conditional knockout (POMC-specific Glp2r-/- and POMC-p110α KO); Co-IP (GLP-2R–p85α); patch clamp for POMC neuron excitability; hyperinsulinemic-euglycemic clamp; FoxO1 nuclear/cytoplasmic fractionation; gluconeogenesis assay","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — Co-IP of receptor-PI3K interaction, patch clamp electrophysiology, and genetic epistasis via two independent KO lines, multiple orthogonal methods","pmids":["23823479"],"is_preprint":false},{"year":2011,"finding":"GLP-2R is expressed on both excitatory (substance P/ChAT-positive) and inhibitory (VIP/nNOS-positive) myenteric and submucosal neurons in mouse duodenum; GLP-2 inhibits smooth muscle contractility by decreasing cholinergic neurotransmission and increasing nitric oxide production, likely via ICC-DMP recruitment.","method":"Immunohistochemistry for GLP-2R co-localization with neuronal markers; in vitro contractility assay of intestinal smooth muscle; nitric oxide pathway pharmacology","journal":"Neurogastroenterology and motility","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-localization with functional contractility assay in vitro, single lab with two orthogonal methods","pmids":["21752156"],"is_preprint":false},{"year":2018,"finding":"GLP-2R signaling controls circulating bile acid levels and relative bile acid species proportions in Gcgr-/- mice (loss of Glp2r in Gcgr-/- background lowers bile acids), and is required for small bowel growth in Gcgr-/- mice; however, GLP-2R is dispensable for glucose homeostasis in Gcgr-/- mice and for metabolic improvements after vertical sleeve gastrectomy.","method":"Double-knockout mice (Gcgr-/-:Glp2r-/-; Gcgr-/-:Gpbar1-/-); Glp2r-/- mice + VSG surgery; bile acid profiling; glucose tolerance testing; intestinal mass measurement","journal":"Molecular metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with multiple double-KO lines and bariatric surgery model, multiple metabolic endpoints, single lab with rigorous controls","pmids":["29937214"],"is_preprint":false},{"year":2020,"finding":"Distal gut Gcg+ endocrine cells are the primary source of GLP-1 secreted in response to GPR119 agonism (AR231453), MC4R agonism (LY2112688), and LPS/TLR activation, as well as the acute GLP-1 response to metformin; in contrast, proximal gut Gcg+ cells are the main source for nutrient-stimulated (olive oil, arginine) GLP-1 secretion.","method":"Intestine-selective Gcg knockdown mice (GcgGut-/- and GcgDistalGut-/-); plasma GLP-1 measurement after administration of diverse secretagogues; glucose measurement","journal":"Molecular metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — two complementary segment-specific genetic reduction models with multiple pharmacologically distinct secretagogues, rigorous epistatic design","pmids":["32278655"],"is_preprint":false},{"year":2020,"finding":"The proliferative effects of GLP-2 in the intestine are partially dependent on the intestinal epithelial IGF-1 receptor (IE-IGF-1R): IE-IGF-1R KO mice show diminished crypt cell proliferative responses to GLP-2 alone or with EGF, while small intestinal weight and crypt-villus height increases are preserved, indicating that GLP-2 acts through EGF and IGF-1R pathways for its proliferative but not its trophic effects.","method":"IE-IGF-1R conditional KO mice treated with GLP-2 and/or EGF; intestinal organoid cultures with EGF/IGF-1 treatment; intestinal growth parameter measurement; crypt cell proliferation assay","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — conditional KO plus organoid reconstitution experiments with multiple growth endpoints, single lab with two orthogonal model systems","pmids":["32147716"],"is_preprint":false},{"year":1984,"finding":"The human glucagon gene (GCG) was mapped to chromosome segment 2q36–37 by in situ hybridization using a 3H-labeled bovine glucagon cDNA probe.","method":"Radioactive in situ hybridization to human metaphase chromosomes","journal":"Cytogenetics and cell genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct chromosomal localization experiment, single lab, single method","pmids":["6546710"],"is_preprint":false},{"year":2017,"finding":"A Gcg CreERT2 knockin mouse was generated by inserting CreERT2 into the endogenous Gcg locus; tamoxifen-induced recombination labeled 94–97% of pancreatic alpha cells, all known proglucagon-producing cell types (L cells, GLP-1-producing neurons), and revealed a glucagon/PP bihormonal cell population (~14–25% of PP+ cells). Intestinal L cells undergo rapid turnover (~half replaced within 2 weeks), whereas alpha cells and GLP-1 neurons persist for ≥5 months post-tamoxifen.","method":"Homologous recombination knockin; Cre-LoxP with Rosa26-tdTomato reporter; immunohistochemistry for cell-type markers; plasma glucagon, GLP-1 measurement","journal":"Diabetologia","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockin with reporter validation across multiple cell types and temporal analysis, multiple orthogonal markers","pmids":["28884202"],"is_preprint":false},{"year":2018,"finding":"GLP-2 dysregulates hepatic lipoprotein metabolism: exogenous GLP-2 administration increases fasting dyslipidemia, hepatic VLDL production, de novo lipogenesis gene expression, and hepatic lipid accumulation in hamsters and mice. Conversely, Glp2r-/- mice show reduced VLDL secretion and microsomal transfer protein activity with exacerbated hepatic lipid accumulation, indicating that GLP-2R signaling is required for normal hepatic lipid/lipoprotein homeostasis.","method":"IP GLP-2 administration in hamsters and C57BL/6J mice; Glp2r-/- mice on HFD; VLDL production assay; hepatic gene expression (lipogenesis genes); MTP lipid transfer activity; liver lipid quantification","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — pharmacological gain-of-function plus genetic loss-of-function in two species with multiple mechanistic endpoints, single lab","pmids":["30052880"],"is_preprint":false},{"year":2021,"finding":"The GLP-2 antiresorptive effect on bone depends on PTH and is likely mediated through GLP-2R expressed in the parathyroid gland, whereas GIP acts directly on bone via GIPR expressed in osteoblasts and osteoclasts independent of PTH. GLP-2R was absent or only weakly expressed in osteoclasts.","method":"Randomized crossover clinical study in hypoparathyroidism patients; subcutaneous GIP and GLP-2 injections; bone turnover markers; GLP-2R and GIPR expression in human osteoblasts, osteoclasts, and parathyroid tissue","journal":"Journal of bone and mineral research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — human clinical epistasis (PTH-deficient patients) combined with receptor expression in relevant cell types, single study","pmids":["33852173"],"is_preprint":false},{"year":2000,"finding":"GLP-2R activation is coupled to increased adenylate cyclase activity; the GLP-2R is expressed in a highly tissue-specific manner predominantly in the gastrointestinal tract (as established by studies of the cloned GLP-2 receptor).","method":"Cloned GLP-2R expressed in heterologous cells; adenylate cyclase/cAMP assay; tissue-specific expression analysis","journal":"Regulatory peptides","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor cloning with functional cAMP coupling assay and tissue expression, review summarizing multiple prior experiments","pmids":["10828489"],"is_preprint":false}],"current_model":"GCG (proglucagon) encodes GLP-1, GLP-2, glucagon, and related peptides that are differentially processed in pancreatic alpha cells versus intestinal L cells and brainstem neurons; GLP-2, the best-characterized intestinal product, signals through a G protein-coupled GLP-2 receptor (primarily on subepithelial myofibroblasts and enteric neurons rather than directly on epithelial cells) to activate cAMP/PKA, PI3K/Akt, and ErbB signaling cascades, promoting intestinal growth via paracrine KGF and ErbB ligand release, suppressing epithelial apoptosis via Bcl-2/caspase pathways, increasing mesenteric blood flow via eNOS activation, modulating hepatic lipid metabolism and bile acid levels, and in the CNS acting on POMC neuron GLP-2R to suppress food intake and enhance hepatic insulin sensitivity through PI3K–FoxO1 and MC4R-dependent pathways."},"narrative":{"mechanistic_narrative":"GCG encodes proglucagon, a precursor that is differentially processed in pancreatic alpha cells versus intestinal L cells and proglucagon-producing neurons to yield glucagon, GLP-1, and GLP-2; intestinal L cells secrete GLP-1 and GLP-2 separately in response to luminal nutrients, distinct from the co-secretion of a larger GLP-containing peptide with glucagon from pancreas [PMID:3530719, PMID:28884202]. Segment-specific Gcg reduction establishes that distal-gut Gcg+ cells supply the GLP-1 evoked by GPR119, MC4R, TLR, and metformin stimulation, whereas proximal-gut cells supply nutrient-stimulated GLP-1 [PMID:32278655]. The intestinotrophic product GLP-2 signals through the G protein-coupled GLP-2 receptor, which couples to adenylate cyclase and activates PKA-dependent transcriptional programs (AP-1, immediate-early genes) while engaging PKA-independent mitogenic mediators [PMID:10521425, PMID:10828489]. GLP-2R is expressed not on the proliferating epithelium itself but on subepithelial myofibroblasts, enteric neurons, and enteroendocrine cells, so its trophic action proceeds through paracrine intermediates: KGF release from myofibroblasts drives colonic growth, and ErbB ligands (amphiregulin, epiregulin, HB-EGF) acting through EGFR/ErbB and intestinal IGF-1R mediate crypt cell proliferation [PMID:10982769, PMID:15544847, PMID:19523469, PMID:32147716]. GLP-2 concurrently suppresses crypt cell apoptosis by inhibiting caspase-8/-3 activation and PARP cleavage and by upregulating Bcl-2 and IAP proteins, and it raises mesenteric blood flow via eNOS activation in VIP/NO enteric neurons [PMID:11212269, PMID:16401478, PMID:16954336]. Beyond the gut, GLP-2R signaling regulates intestinal motility through cholinergic and nitrergic neurons [PMID:21752156], hepatic lipoprotein and bile acid homeostasis [PMID:29937214, PMID:30052880], bone resorption via a PTH-dependent parathyroid mechanism [PMID:33852173], and—through POMC neuron GLP-2R—suppresses food intake and gastric emptying via MC4R and enhances hepatic insulin sensitivity through a GLP-2R–p85α/PI3K–Akt–FoxO1 axis [PMID:22829581, PMID:23823479]. The DPP-IV cleavage product GLP-2(3-33) acts as a partial agonist/competitive antagonist at the receptor [PMID:11738243].","teleology":[{"year":1986,"claim":"Established that proglucagon products are processed and secreted differently by tissue, resolving how one gene yields distinct intestinal versus pancreatic peptides.","evidence":"RIA, HPLC on isolated perfused pig pancreas and ileum","pmids":["3530719"],"confidence":"High","gaps":["Did not identify the processing enzymes responsible for tissue-specific cleavage","Functional roles of secreted GLP-1/GLP-2 not addressed"]},{"year":1984,"claim":"Localized the human GCG gene to a chromosomal locus, providing the genomic anchor for the proglucagon gene.","evidence":"Radioactive in situ hybridization to human metaphase chromosomes","pmids":["6546710"],"confidence":"Medium","gaps":["Single method, single lab","No functional or regulatory information about the locus"]},{"year":1999,"claim":"Defined the GLP-2 receptor as a cAMP/PKA-coupled GPCR and showed that mitogenic signaling involves PKA-independent mediators, separating second-messenger generation from growth output.","evidence":"Transfected BHK cells expressing rat GLP-2R; cAMP, luciferase reporters, dominant-negative PKA, immunoblotting","pmids":["10521425"],"confidence":"High","gaps":["Heterologous cell system, not native epithelium","Identity of PKA-independent mitogenic mediators undefined"]},{"year":2000,"claim":"Mapped GLP-2R expression to enteroendocrine cells, brain, and lung, raising the key insight that epithelial trophic effects must be indirect.","evidence":"Northern blot, RT-PCR, immunocytochemistry across rodent and human tissues; cloned receptor cAMP coupling","pmids":["10982769","10828489"],"confidence":"High","gaps":["Did not identify which downstream mediators relay the signal to epithelium","Cell-type resolution limited at this stage"]},{"year":2001,"claim":"Showed GLP-2R activation is anti-apoptotic and that central GLP-2 suppresses feeding, expanding the receptor's role to cell survival and CNS energy balance.","evidence":"Caspase/PARP assays in transfected cells with murine chemotherapy models; ICV injection in WT and GLP-1R-/- mice with antagonist and reporter","pmids":["11212269","11262390"],"confidence":"High","gaps":["Anti-apoptotic mechanism in transfected cells not yet linked to specific epithelial pathway","CNS GLP-2R-expressing neuronal populations not resolved"]},{"year":2002,"claim":"Characterized the DPP-IV product GLP-2(3-33) as a partial agonist/competitive antagonist, defining a built-in regulatory brake on GLP-2 signaling.","evidence":"Receptor binding and cAMP in human GLP-2R cells; in vivo co-administration intestinal growth assay","pmids":["11738243"],"confidence":"High","gaps":["Physiological concentrations achieving antagonism in vivo unclear","No structural basis for partial agonism"]},{"year":2005,"claim":"Identified KGF from subepithelial myofibroblasts as an obligate paracrine mediator of colonic GLP-2 trophic action, providing the first molecular intermediate for indirect epithelial growth.","evidence":"IHC/ISH for GLP-2R on myofibroblasts; anti-KGF neutralization in vivo in mice","pmids":["15544847"],"confidence":"High","gaps":["KGF dependence does not explain small intestinal growth","Other paracrine mediators not yet identified"]},{"year":2006,"claim":"Demonstrated that GLP-2 increases mesenteric blood flow via eNOS in enteric neurons and rapidly activates divergent pro-survival/pro-growth signaling in epithelium, connecting receptor activation to vascular and trophic physiology.","evidence":"qRT-PCR on LCM tissue, FISH, confocal triple immunostaining, blood flow measurement in neonatal pigs; in vivo GLP-2 infusion time-course in TPN-fed piglets","pmids":["16401478","16954336"],"confidence":"High","gaps":["Epithelial signaling in piglets correlative as to which are GLP-2R-direct versus paracrine","Single species per study"]},{"year":2009,"claim":"Established ErbB ligand release and EGFR/ErbB signaling as required for GLP-2 proliferative and bowel-growth effects, and showed GLP-2 modulates VGCC in neurons, defining the dominant trophic effector and a neuronal action.","evidence":"Gene profiling and epistasis in WT, Glp2r-/-, Egfr(wa2) mice with pan-ErbB inhibitor; patch clamp and radioligand binding in hippocampal neurons","pmids":["19523469","19920220"],"confidence":"High","gaps":["Mechanism linking GLP-2R to metalloproteinase-dependent ErbB ligand shedding incomplete","Physiological role of neuronal VGCC potentiation unclear"]},{"year":2011,"claim":"Resolved GLP-2R expression on excitatory and inhibitory enteric neurons and its inhibition of smooth muscle contractility, linking the receptor to gut motility control.","evidence":"IHC co-localization with neuronal markers; in vitro intestinal smooth muscle contractility with NO pathway pharmacology","pmids":["21752156"],"confidence":"Medium","gaps":["ICC-DMP involvement inferred not demonstrated","Single lab, in vitro contractility only"]},{"year":2012,"claim":"Identified POMC neuron GLP-2R as the substrate for central anorectic and gastric-emptying effects and showed MC4R-dependence, mapping the CNS circuit for GLP-2 action.","evidence":"POMC-specific Glp2r conditional KO, ICV GLP-2, MC4R KO epistasis, gastric emptying breath test","pmids":["22829581"],"confidence":"High","gaps":["Source of endogenous ligand reaching POMC neurons unclear","Link between POMC GLP-2R and downstream melanocortin release not detailed"]},{"year":2013,"claim":"Defined a GLP-2R–p85α/PI3K–Akt–FoxO1 axis in POMC neurons controlling hepatic glucose production, establishing a direct receptor–PI3K physical and functional link for central glucose regulation.","evidence":"POMC-specific Glp2r and p110α KO; Co-IP of GLP-2R–p85α; patch clamp; hyperinsulinemic-euglycemic clamp; FoxO1 fractionation","pmids":["23823479"],"confidence":"High","gaps":["GLP-2R–p85α interaction shown by Co-IP without structural detail","Whether interaction is direct or scaffolded not resolved"]},{"year":2017,"claim":"Created a Gcg lineage-tracing tool that catalogued all proglucagon-producing cell types and their turnover, providing the cellular map underlying tissue-specific GCG biology.","evidence":"Gcg-CreERT2 knockin with tdTomato reporter, IHC marker analysis, plasma hormone measurement","pmids":["28884202"],"confidence":"High","gaps":["Did not test functional consequences of cell turnover on peptide output","Bihormonal glucagon/PP cell function unexplored"]},{"year":2018,"claim":"Showed GLP-2R signaling governs hepatic lipoprotein metabolism and, in the Gcgr-/- background, controls bile acid levels and is required for small bowel growth while being dispensable for glucose homeostasis, distinguishing GLP-2R-dependent from -independent metabolic functions.","evidence":"VLDL/MTP assays and Glp2r-/- mice; double-KO mice (Gcgr-/-:Glp2r-/-, Gcgr-/-:Gpbar1-/-), VSG surgery, bile acid profiling","pmids":["30052880","29937214"],"confidence":"High","gaps":["Tissue site of GLP-2R action on hepatic lipid not localized","Mechanism connecting GLP-2R to bile acid handling undefined"]},{"year":2020,"claim":"Pinpointed proximal versus distal Gcg+ cells as differential sources of secretagogue-specific GLP-1, and showed intestinal IGF-1R is required for GLP-2 proliferative but not trophic effects, refining both the source and effector arms of the pathway.","evidence":"Segment-specific Gcg knockdown mice with diverse secretagogues; IE-IGF-1R conditional KO and organoid reconstitution","pmids":["32278655","32147716"],"confidence":"High","gaps":["How proliferative and trophic effects are mechanistically separated at the receptor level unclear","Relative contributions of EGF versus IGF-1 axes not quantified"]},{"year":2021,"claim":"Established that the GLP-2 antiresorptive bone effect is PTH-dependent via parathyroid GLP-2R, contrasting with the direct osteoblast/osteoclast action of GIP, defining an endocrine relay for skeletal regulation.","evidence":"Randomized crossover clinical study in hypoparathyroidism patients; bone turnover markers; receptor expression in human bone and parathyroid tissue","pmids":["33852173"],"confidence":"Medium","gaps":["Single clinical study","Direct demonstration of parathyroid GLP-2R signaling causing PTH change not shown"]},{"year":null,"claim":"The proteases and regulatory inputs that route proglucagon toward glucagon versus GLP-1/GLP-2 in different cell types, and the structural basis of GLP-2R coupling to its divergent paracrine and PI3K effectors, remain unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No timeline finding identifies the cell-specific proglucagon processing enzymes","No structural model of GLP-2R or its p85α interaction","Direct epithelial versus paracrine partitioning of GLP-2 effects incompletely quantified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,5,15]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,21]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,15,18]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,12,21]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[14,19]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[6,9,16]}],"complexes":[],"partners":["GLP2R"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P01275","full_name":"Pro-glucagon","aliases":[],"length_aa":180,"mass_kda":20.9,"function":"Plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes. Binds to and activates the glucagon receptor GCGR, which couples to the G(s) G protein and elevates intracellular cAMP, triggering downstream metabolic responses (PubMed:32193322) Potent stimulator of glucose-dependent insulin release (PubMed:22037645, PubMed:40446798). Also stimulates insulin release in response to IL6 (PubMed:22037645). Plays important roles on gastric motility and the suppression of plasma glucagon levels (PubMed:10605628, PubMed:14719035, PubMed:12554744). May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin (PubMed:10605628, PubMed:14719035, PubMed:12554744). Has growth-promoting activities on intestinal epithelium (PubMed:10605628, PubMed:14719035, PubMed:12554744). May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion (PubMed:10605628, PubMed:14719035, PubMed:12554744). Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation (PubMed:10605628, PubMed:14719035, PubMed:12554744). Inhibits beta cell apoptosis (PubMed:10605628, PubMed:14719035, PubMed:12554744) Stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability Significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness May modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P01275/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GCG","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GCG","total_profiled":1310},"omim":[{"mim_id":"620346","title":"MAJOR FACILITATOR SUPERFAMILY DOMAIN-CONTAINING PROTEIN 11; MFSD11","url":"https://www.omim.org/entry/620346"},{"mim_id":"620340","title":"NIPA-LIKE DOMAIN-CONTAINING PROTEIN 1; NIPAL1","url":"https://www.omim.org/entry/620340"},{"mim_id":"612880","title":"SYNAPTOTAGMIN-LIKE 2; SYTL2","url":"https://www.omim.org/entry/612880"},{"mim_id":"608981","title":"ACTIVIN A RECEPTOR, TYPE IC; ACVR1C","url":"https://www.omim.org/entry/608981"},{"mim_id":"608145","title":"NIPA MAGNESIUM TRANSPORTER 1; NIPA1","url":"https://www.omim.org/entry/608145"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Endoplasmic reticulum","reliability":"Approved"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"pancreas","ntpm":1834.3}],"url":"https://www.proteinatlas.org/search/GCG"},"hgnc":{"alias_symbol":["GLP1","GLP2","GRPP","GLP-1"],"prev_symbol":[]},"alphafold":{"accession":"P01275","domains":[{"cath_id":"-","chopping":"107-144","consensus_level":"medium","plddt":71.8647,"start":107,"end":144},{"cath_id":"1.20.5","chopping":"151-180","consensus_level":"medium","plddt":81.338,"start":151,"end":180}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P01275","model_url":"https://alphafold.ebi.ac.uk/files/AF-P01275-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P01275-F1-predicted_aligned_error_v6.png","plddt_mean":68.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GCG","jax_strain_url":"https://www.jax.org/strain/search?query=GCG"},"sequence":{"accession":"P01275","fasta_url":"https://rest.uniprot.org/uniprotkb/P01275.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P01275/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P01275"}},"corpus_meta":[{"pmid":"9462747","id":"PMC_9462747","title":"Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy.","date":"1998","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9462747","citation_count":627,"is_preprint":false},{"pmid":"3530719","id":"PMC_3530719","title":"Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas.","date":"1986","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/3530719","citation_count":444,"is_preprint":false},{"pmid":"10982769","id":"PMC_10982769","title":"Enteroendocrine localization of GLP-2 receptor expression in humans and rodents.","date":"2000","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/10982769","citation_count":283,"is_preprint":false},{"pmid":"16401478","id":"PMC_16401478","title":"GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow.","date":"2006","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/16401478","citation_count":220,"is_preprint":false},{"pmid":"9815019","id":"PMC_9815019","title":"GLP-2 augments the adaptive response to massive intestinal resection in rat.","date":"1998","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/9815019","citation_count":189,"is_preprint":false},{"pmid":"6181416","id":"PMC_6181416","title":"Molecular structure of r(GCG)d(TATACGC): a DNA--RNA hybrid helix joined to double helical DNA.","date":"1982","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/6181416","citation_count":185,"is_preprint":false},{"pmid":"15544847","id":"PMC_15544847","title":"GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors.","date":"2005","source":"Regulatory peptides","url":"https://pubmed.ncbi.nlm.nih.gov/15544847","citation_count":179,"is_preprint":false},{"pmid":"23892476","id":"PMC_23892476","title":"The gut microbiota reduces leptin sensitivity and the expression of the obesity-suppressing neuropeptides proglucagon (Gcg) and brain-derived neurotrophic factor (Bdnf) in the central nervous system.","date":"2013","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/23892476","citation_count":168,"is_preprint":false},{"pmid":"11093948","id":"PMC_11093948","title":"GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis.","date":"2000","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11093948","citation_count":156,"is_preprint":false},{"pmid":"9886982","id":"PMC_9886982","title":"Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis.","date":"1999","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/9886982","citation_count":151,"is_preprint":false},{"pmid":"34932984","id":"PMC_34932984","title":"Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist.","date":"2021","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34932984","citation_count":145,"is_preprint":false},{"pmid":"12529935","id":"PMC_12529935","title":"Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors.","date":"2002","source":"Receptors & channels","url":"https://pubmed.ncbi.nlm.nih.gov/12529935","citation_count":140,"is_preprint":false},{"pmid":"19587282","id":"PMC_19587282","title":"A triplet repeat expansion genetic mouse model of infantile spasms syndrome, Arx(GCG)10+7, with interneuronopathy, spasms in infancy, persistent seizures, and adult cognitive and behavioral impairment.","date":"2009","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/19587282","citation_count":138,"is_preprint":false},{"pmid":"3576119","id":"PMC_3576119","title":"Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2).","date":"1987","source":"Scandinavian journal of clinical and laboratory investigation","url":"https://pubmed.ncbi.nlm.nih.gov/3576119","citation_count":137,"is_preprint":false},{"pmid":"11212269","id":"PMC_11212269","title":"Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11212269","citation_count":127,"is_preprint":false},{"pmid":"20638440","id":"PMC_20638440","title":"Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides.","date":"2010","source":"Progress in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/20638440","citation_count":119,"is_preprint":false},{"pmid":"7031665","id":"PMC_7031665","title":"Base-pair substitution hotspots in GAG and GCG nucleotide sequences in Escherichia coli K-12 induced by cis-diamminedichloroplatinum (II).","date":"1981","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7031665","citation_count":111,"is_preprint":false},{"pmid":"33837182","id":"PMC_33837182","title":"GCG inhibits SARS-CoV-2 replication by disrupting the liquid phase condensation of its nucleocapsid protein.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33837182","citation_count":104,"is_preprint":false},{"pmid":"15388486","id":"PMC_15388486","title":"Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome.","date":"2004","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15388486","citation_count":101,"is_preprint":false},{"pmid":"11262390","id":"PMC_11262390","title":"Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11262390","citation_count":99,"is_preprint":false},{"pmid":"3954991","id":"PMC_3954991","title":"Raman spectra of single crystals of r(GCG)d(CGC) and d(CCCCGGGG) as models for A DNA, their structure transitions in aqueous solution, and comparison with double-helical poly(dG).poly(dC).","date":"1986","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3954991","citation_count":90,"is_preprint":false},{"pmid":"19523469","id":"PMC_19523469","title":"ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut.","date":"2009","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/19523469","citation_count":88,"is_preprint":false},{"pmid":"10521425","id":"PMC_10521425","title":"Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10521425","citation_count":88,"is_preprint":false},{"pmid":"23823479","id":"PMC_23823479","title":"Central GLP-2 enhances hepatic insulin sensitivity via activating PI3K signaling in POMC neurons.","date":"2013","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23823479","citation_count":86,"is_preprint":false},{"pmid":"11705785","id":"PMC_11705785","title":"GLP-2 has differential effects on small intestine growth and function in fetal and neonatal pigs.","date":"2001","source":"American journal of physiology. Regulatory, integrative and comparative physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11705785","citation_count":83,"is_preprint":false},{"pmid":"12505881","id":"PMC_12505881","title":"Role of luminal nutrients and endogenous GLP-2 in intestinal adaptation to mid-small bowel resection.","date":"2002","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12505881","citation_count":77,"is_preprint":false},{"pmid":"15548172","id":"PMC_15548172","title":"Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage.","date":"2004","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/15548172","citation_count":75,"is_preprint":false},{"pmid":"11738243","id":"PMC_11738243","title":"The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist.","date":"2002","source":"Regulatory peptides","url":"https://pubmed.ncbi.nlm.nih.gov/11738243","citation_count":75,"is_preprint":false},{"pmid":"22829581","id":"PMC_22829581","title":"GLP-2 receptor in POMC neurons suppresses feeding behavior and gastric motility.","date":"2012","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22829581","citation_count":67,"is_preprint":false},{"pmid":"29473979","id":"PMC_29473979","title":"A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease.","date":"2018","source":"Hippocampus","url":"https://pubmed.ncbi.nlm.nih.gov/29473979","citation_count":59,"is_preprint":false},{"pmid":"32278655","id":"PMC_32278655","title":"Intestine-selective reduction of Gcg expression reveals the importance of the distal gut for GLP-1 secretion.","date":"2020","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32278655","citation_count":58,"is_preprint":false},{"pmid":"12771317","id":"PMC_12771317","title":"Introduction of enteral food increases plasma GLP-2 and decreases GLP-2 receptor mRNA abundance during pig development.","date":"2003","source":"The Journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/12771317","citation_count":57,"is_preprint":false},{"pmid":"27048234","id":"PMC_27048234","title":"GLP2: an underestimated signal for improving glycaemic control and insulin sensitivity.","date":"2016","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27048234","citation_count":52,"is_preprint":false},{"pmid":"15201402","id":"PMC_15201402","title":"GLP-2 levels in infants with intestinal dysfunction.","date":"2004","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/15201402","citation_count":52,"is_preprint":false},{"pmid":"23189208","id":"PMC_23189208","title":"GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23189208","citation_count":50,"is_preprint":false},{"pmid":"10828489","id":"PMC_10828489","title":"New frontiers in the biology of GLP-2.","date":"2000","source":"Regulatory peptides","url":"https://pubmed.ncbi.nlm.nih.gov/10828489","citation_count":50,"is_preprint":false},{"pmid":"15568286","id":"PMC_15568286","title":"Comparative effects of glucagon-like peptide-2 (GLP-2), growth hormone (GH), and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats.","date":"2004","source":"JPEN. Journal of parenteral and enteral nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/15568286","citation_count":50,"is_preprint":false},{"pmid":"23757509","id":"PMC_23757509","title":"Alteration of the intestinal barrier and GLP2 secretion in Berberine-treated type 2 diabetic rats.","date":"2013","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/23757509","citation_count":49,"is_preprint":false},{"pmid":"6193486","id":"PMC_6193486","title":"Proton NMR studies on the covalently linked RNA-DNA hybrid r(GCG)d(TATACGC). Assignment of proton resonances by application of the nuclear Overhauser effect.","date":"1983","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/6193486","citation_count":49,"is_preprint":false},{"pmid":"6856460","id":"PMC_6856460","title":"Specifically alkylated DNA fragments. Synthesis and physical characterization of d[CGC(O6Me)GCG] and d[CGT(O6Me)GCG].","date":"1983","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/6856460","citation_count":49,"is_preprint":false},{"pmid":"1390625","id":"PMC_1390625","title":"Conformation of guanine-8-oxoadenine base pairs in the crystal structure of d(CGCGAATT(O8A)GCG).","date":"1992","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1390625","citation_count":49,"is_preprint":false},{"pmid":"16954336","id":"PMC_16954336","title":"GLP-2 rapidly activates divergent intracellular signaling pathways involved in intestinal cell survival and proliferation in neonatal piglets.","date":"2006","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16954336","citation_count":48,"is_preprint":false},{"pmid":"16908079","id":"PMC_16908079","title":"DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells.","date":"2006","source":"Regulatory peptides","url":"https://pubmed.ncbi.nlm.nih.gov/16908079","citation_count":46,"is_preprint":false},{"pmid":"12919941","id":"PMC_12919941","title":"Effect of GLP-2 on mucosal morphology and SGLT1 expression in tissue-engineered neointestine.","date":"2003","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12919941","citation_count":45,"is_preprint":false},{"pmid":"10680791","id":"PMC_10680791","title":"GCG genetic expansions in Italian patients with oculopharyngeal muscular dystrophy.","date":"2000","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/10680791","citation_count":45,"is_preprint":false},{"pmid":"22809889","id":"PMC_22809889","title":"GLP-2 enhances barrier formation and attenuates TNFα-induced changes in a Caco-2 cell model of the intestinal barrier.","date":"2012","source":"Regulatory peptides","url":"https://pubmed.ncbi.nlm.nih.gov/22809889","citation_count":44,"is_preprint":false},{"pmid":"25116357","id":"PMC_25116357","title":"GLP-2 suppresses LPS-induced inflammation in macrophages by inhibiting ERK phosphorylation and NF-κB activation.","date":"2014","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25116357","citation_count":43,"is_preprint":false},{"pmid":"9682058","id":"PMC_9682058","title":"W2H: WWW interface to the GCG sequence analysis package.","date":"1998","source":"Bioinformatics (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/9682058","citation_count":43,"is_preprint":false},{"pmid":"11087766","id":"PMC_11087766","title":"Oculopharyngeal MD among Bukhara Jews is due to a founder (GCG)9 mutation in the PABP2 gene.","date":"2000","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/11087766","citation_count":42,"is_preprint":false},{"pmid":"15514259","id":"PMC_15514259","title":"Increased expression of specific intestinal amino acid and peptide transporter mRNA in rats fed by TPN is reversed by GLP-2.","date":"2004","source":"The Journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/15514259","citation_count":42,"is_preprint":false},{"pmid":"18443137","id":"PMC_18443137","title":"Exogenous glucagon-like peptide-2 (GLP-2) augments GLP-2 receptor mRNA and maintains proglucagon mRNA levels in resected rats.","date":"2008","source":"JPEN. Journal of parenteral and enteral nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/18443137","citation_count":41,"is_preprint":false},{"pmid":"21752156","id":"PMC_21752156","title":"GLP-2 receptor expression in excitatory and inhibitory enteric neurons and its role in mouse duodenum contractility.","date":"2011","source":"Neurogastroenterology and motility","url":"https://pubmed.ncbi.nlm.nih.gov/21752156","citation_count":40,"is_preprint":false},{"pmid":"18365267","id":"PMC_18365267","title":"GCG-rich tea catechins are effective in lowering cholesterol and triglyceride concentrations in hyperlipidemic rats.","date":"2008","source":"Lipids","url":"https://pubmed.ncbi.nlm.nih.gov/18365267","citation_count":40,"is_preprint":false},{"pmid":"25967277","id":"PMC_25967277","title":"GLP-2 as Beneficial Factor in the Glucose Homeostasis in Mice Fed a High Fat Diet.","date":"2015","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25967277","citation_count":40,"is_preprint":false},{"pmid":"32219218","id":"PMC_32219218","title":"The Discovery of GLP-2 and Development of Teduglutide for Short Bowel Syndrome.","date":"2019","source":"ACS pharmacology & translational science","url":"https://pubmed.ncbi.nlm.nih.gov/32219218","citation_count":39,"is_preprint":false},{"pmid":"25218018","id":"PMC_25218018","title":"GLP-2: what do we know? What are we going to discover?","date":"2014","source":"Regulatory peptides","url":"https://pubmed.ncbi.nlm.nih.gov/25218018","citation_count":37,"is_preprint":false},{"pmid":"15755680","id":"PMC_15755680","title":"Transgenic expression of an expanded (GCG)13 repeat PABPN1 leads to weakness and coordination defects in mice.","date":"2005","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/15755680","citation_count":37,"is_preprint":false},{"pmid":"34995796","id":"PMC_34995796","title":"GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment.","date":"2022","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/34995796","citation_count":37,"is_preprint":false},{"pmid":"8064857","id":"PMC_8064857","title":"The solution structure of the r(gcg)d(TATACCC):d(GGGTATACGC) Okazaki fragment contains two distinct duplex morphologies connected by a junction.","date":"1994","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8064857","citation_count":37,"is_preprint":false},{"pmid":"20418955","id":"PMC_20418955","title":"Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20418955","citation_count":37,"is_preprint":false},{"pmid":"30364471","id":"PMC_30364471","title":"GLP-2 analog teduglutide significantly reduces need for parenteral nutrition and stool frequency in a real-life setting.","date":"2018","source":"Therapeutic advances in gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/30364471","citation_count":37,"is_preprint":false},{"pmid":"25500730","id":"PMC_25500730","title":"A tetrahelical DNA fold adopted by tandem repeats of alternating GGG and GCG tracts.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25500730","citation_count":36,"is_preprint":false},{"pmid":"28884202","id":"PMC_28884202","title":"Gcg CreERT2 knockin mice as a tool for genetic manipulation in pancreatic alpha cells.","date":"2017","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/28884202","citation_count":35,"is_preprint":false},{"pmid":"32454171","id":"PMC_32454171","title":"Anti-melanogenic effects of epigallocatechin-3-gallate (EGCG), epicatechin-3-gallate (ECG) and gallocatechin-3-gallate (GCG) via down-regulation of cAMP/CREB /MITF signaling pathway in B16F10 melanoma cells.","date":"2020","source":"Fitoterapia","url":"https://pubmed.ncbi.nlm.nih.gov/32454171","citation_count":34,"is_preprint":false},{"pmid":"6546710","id":"PMC_6546710","title":"Localization of the human glucagon gene (GCG) to chromosome segment 2q36----37.","date":"1984","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/6546710","citation_count":34,"is_preprint":false},{"pmid":"15573929","id":"PMC_15573929","title":"Plasma GLP-2 levels and intestinal markers in the juvenile pig during intestinal adaptation: effects of different diet regimens.","date":"2004","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15573929","citation_count":33,"is_preprint":false},{"pmid":"32147454","id":"PMC_32147454","title":"A GLP-1/GIP/Gcg receptor triagonist improves memory behavior, as well as synaptic transmission, neuronal excitability and Ca2+ homeostasis in 3xTg-AD mice.","date":"2020","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32147454","citation_count":32,"is_preprint":false},{"pmid":"12496980","id":"PMC_12496980","title":"Association between the GCG polymorphism of the selenium dependent GPX1 gene and the risk of young onset prostate cancer.","date":"2002","source":"Prostate cancer and prostatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/12496980","citation_count":32,"is_preprint":false},{"pmid":"14965320","id":"PMC_14965320","title":"Glucagon-like peptide 2 (GLP-2), an intestinotrophic mediator.","date":"2004","source":"Current protein & peptide science","url":"https://pubmed.ncbi.nlm.nih.gov/14965320","citation_count":31,"is_preprint":false},{"pmid":"33852173","id":"PMC_33852173","title":"The Antiresorptive Effect of GIP, But Not GLP-2, Is Preserved in Patients With Hypoparathyroidism-A Randomized Crossover Study.","date":"2021","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/33852173","citation_count":31,"is_preprint":false},{"pmid":"28462383","id":"PMC_28462383","title":"Interdependency of EGF and GLP-2 Signaling in Attenuating Mucosal Atrophy in a Mouse Model of Parenteral Nutrition.","date":"2017","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/28462383","citation_count":31,"is_preprint":false},{"pmid":"32398684","id":"PMC_32398684","title":"Dipeptidyl peptidase 4 inhibitor sitagliptin protected against dextran sulfate sodium-induced experimental colitis by potentiating the action of GLP-2.","date":"2020","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/32398684","citation_count":30,"is_preprint":false},{"pmid":"8161534","id":"PMC_8161534","title":"Guanine-1,N6-ethenoadenine base pairs in the crystal structure of d(CGCGAATT(epsilon dA)GCG).","date":"1994","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8161534","citation_count":30,"is_preprint":false},{"pmid":"34705281","id":"PMC_34705281","title":"Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel.","date":"2021","source":"JPEN. Journal of parenteral and enteral nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/34705281","citation_count":29,"is_preprint":false},{"pmid":"31447774","id":"PMC_31447774","title":"Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats.","date":"2019","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31447774","citation_count":29,"is_preprint":false},{"pmid":"26986178","id":"PMC_26986178","title":"Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance.","date":"2016","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26986178","citation_count":28,"is_preprint":false},{"pmid":"10734263","id":"PMC_10734263","title":"Oculopharyngeal muscular dystrophy in a Japanese family with a short GCG expansion (GCG)(11) in PABP2 gene.","date":"2000","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/10734263","citation_count":27,"is_preprint":false},{"pmid":"15327523","id":"PMC_15327523","title":"Patient interleukin-18 GCG haplotype associates with improved survival and decreased transplant-related mortality after unrelated-donor bone marrow transplantation.","date":"2004","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/15327523","citation_count":27,"is_preprint":false},{"pmid":"11150975","id":"PMC_11150975","title":"GCG repeats and phenotype in oculopharyngeal muscular dystrophy.","date":"2001","source":"Muscle & nerve","url":"https://pubmed.ncbi.nlm.nih.gov/11150975","citation_count":27,"is_preprint":false},{"pmid":"32147716","id":"PMC_32147716","title":"GLP-2, EGF, and the Intestinal Epithelial IGF-1 Receptor Interactions in the Regulation of Crypt Cell Proliferation.","date":"2020","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32147716","citation_count":24,"is_preprint":false},{"pmid":"30893514","id":"PMC_30893514","title":"GC-(4→8)-GCG, A Proanthocyanidin Dimer from Camellia ptilophylla, Modulates Obesity and Adipose Tissue Inflammation in High-Fat Diet Induced Obese Mice.","date":"2019","source":"Molecular nutrition & food research","url":"https://pubmed.ncbi.nlm.nih.gov/30893514","citation_count":24,"is_preprint":false},{"pmid":"20688461","id":"PMC_20688461","title":"Expression of mRNA for proglucagon and glucagon-like peptide-2 (GLP-2) receptor in the ruminant gastrointestinal tract and the influence of energy intake.","date":"2010","source":"Domestic animal endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/20688461","citation_count":24,"is_preprint":false},{"pmid":"37446194","id":"PMC_37446194","title":"EGCG, GCG, TFDG, or TSA Inhibiting Melanin Synthesis by Downregulating MC1R Expression.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37446194","citation_count":23,"is_preprint":false},{"pmid":"8486678","id":"PMC_8486678","title":"Simultaneous incorporations of two anticancer drugs into DNA. The structures of formaldehyde-cross-linked adducts of daunorubicin-d(CG(araC)GCG) and doxorubicin-d(CA(araC)GTG) complexes at high resolution.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8486678","citation_count":23,"is_preprint":false},{"pmid":"19920220","id":"PMC_19920220","title":"GLP-2 potentiates L-type Ca2+ channel activity associated with stimulated glucose uptake in hippocampal neurons.","date":"2009","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19920220","citation_count":23,"is_preprint":false},{"pmid":"29937214","id":"PMC_29937214","title":"GLP-2 receptor signaling controls circulating bile acid levels but not glucose homeostasis in Gcgr-/- mice and is dispensable for the metabolic benefits ensuing after vertical sleeve gastrectomy.","date":"2018","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/29937214","citation_count":23,"is_preprint":false},{"pmid":"28724693","id":"PMC_28724693","title":"New Peptide Inhibitor of Dipeptidyl Peptidase IV, EMDB-1 Extends the Half-Life of GLP-2 and Attenuates Colitis in Mice after Topical Administration.","date":"2017","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/28724693","citation_count":23,"is_preprint":false},{"pmid":"20112065","id":"PMC_20112065","title":"The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin.","date":"2010","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/20112065","citation_count":23,"is_preprint":false},{"pmid":"31730763","id":"PMC_31730763","title":"Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury.","date":"2019","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31730763","citation_count":22,"is_preprint":false},{"pmid":"28746825","id":"PMC_28746825","title":"Differential expression of glucagon-like peptide-2 (GLP-2) is involved in pancreatic islet cell adaptations to stress and beta-cell survival.","date":"2017","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/28746825","citation_count":22,"is_preprint":false},{"pmid":"20167840","id":"PMC_20167840","title":"GLP-2 receptor agonism ameliorates inflammation and gastrointestinal stasis in murine postoperative ileus.","date":"2010","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/20167840","citation_count":22,"is_preprint":false},{"pmid":"28523577","id":"PMC_28523577","title":"FFA3 Activation Stimulates Duodenal Bicarbonate Secretion and Prevents NSAID-Induced Enteropathy via the GLP-2 Pathway in Rats.","date":"2017","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28523577","citation_count":22,"is_preprint":false},{"pmid":"35484823","id":"PMC_35484823","title":"A GLP-1/glucagon (GCG)/CCK2 receptors tri-agonist provides new therapy for obesity and diabetes.","date":"2022","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35484823","citation_count":21,"is_preprint":false},{"pmid":"32006214","id":"PMC_32006214","title":"GLP-2 Acutely Prevents Endotoxin-Related Increased Intestinal Paracellular Permeability in Rats.","date":"2020","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32006214","citation_count":21,"is_preprint":false},{"pmid":"11193827","id":"PMC_11193827","title":"New developments in the biology of the glucagon-like peptides GLP-1 and GLP-2.","date":"2000","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/11193827","citation_count":21,"is_preprint":false},{"pmid":"30052880","id":"PMC_30052880","title":"GLP-2 Dysregulates Hepatic Lipoprotein Metabolism, Inducing Fatty Liver and VLDL Overproduction in Male Hamsters and Mice.","date":"2018","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30052880","citation_count":21,"is_preprint":false},{"pmid":"32060615","id":"PMC_32060615","title":"The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats.","date":"2020","source":"Cancer chemotherapy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32060615","citation_count":21,"is_preprint":false},{"pmid":"31765661","id":"PMC_31765661","title":"A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP/PS1 transgenic mice.","date":"2019","source":"Hormones and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/31765661","citation_count":20,"is_preprint":false},{"pmid":"35933503","id":"PMC_35933503","title":"Therapeutic Potential of GLP-2 Analogs in Gastrointestinal Disorders: Current Knowledge, Nutritional Aspects, and Future Perspectives.","date":"2022","source":"Current nutrition reports","url":"https://pubmed.ncbi.nlm.nih.gov/35933503","citation_count":20,"is_preprint":false},{"pmid":"33112876","id":"PMC_33112876","title":"APC mutations in human colon lead to decreased neuroendocrine maturation of ALDH+ stem cells that alters GLP-2 and SST feedback signaling: Clue to a link between WNT and retinoic acid signalling in colon cancer development.","date":"2020","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/33112876","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":56039,"output_tokens":6055,"usd":0.129471,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14779,"output_tokens":5204,"usd":0.101998,"stage2_stop_reason":"end_turn"},"total_usd":0.231469,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1986,\n      \"finding\": \"GLP-1 and GLP-2 (predicted products of the proglucagon/GCG gene) are secreted separately from pig small intestine L cells (glicentin-producing cells) in parallel with intestinal glicentin upon luminal glucose or GRP stimulation, whereas pancreatic GCG expression yields a large peptide containing both GLP-1 and GLP-2 immunoreactivity co-secreted with glucagon upon arginine stimulation.\",\n      \"method\": \"RIA with specific antisera, reverse-phase HPLC, isolated perfused pig pancreas and ileum\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro/ex vivo secretion assay with HPLC characterization, replicated across two different tissue preparations\",\n      \"pmids\": [\"3530719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"GLP-2 signals through the GLP-2 receptor (a G protein-coupled receptor) to activate cAMP accumulation and PKA-dependent AP-1 transcriptional activity; it also stimulates c-fos, c-jun, junB and zif268 expression and transiently increases p70 S6 kinase, while inhibiting ERK1/2 and reducing serum-stimulated Elk-1 activity. Critically, 8-bromo-cAMP alone did not promote cell proliferation, indicating that GLP-2R mitogenic signaling involves PKA-independent downstream mediators.\",\n      \"method\": \"Transfected BHK cells expressing rat GLP-2R; cAMP assay, luciferase reporter assays, dominant-negative PKA inhibitor, immunoblotting\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal signaling assays in a defined cell system with dominant-negative controls, single lab\",\n      \"pmids\": [\"10521425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"GLP-2 receptor (GLP-2R) is expressed in enteroendocrine cells of the stomach, small bowel, and colon epithelium in humans and rodents, and also in the hypothalamus, brain stem, and lung, suggesting indirect epithelial action via downstream mediators.\",\n      \"method\": \"Northern blotting, RT-PCR, immunocytochemistry on rodent and human tissues\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal localization methods in two species, replicated in multiple tissue types\",\n      \"pmids\": [\"10982769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"GLP-2 receptor activation suppresses crypt cell apoptosis through inhibition of caspase-8 and caspase-3 activation and inhibition of PARP cleavage, as demonstrated in heterologous cells transfected with the GLP-2 receptor.\",\n      \"method\": \"Cells transfected with GLP-2 receptor; caspase-8/-3 activity assays, PARP cleavage by Western blot; murine chemotherapy models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined cellular mechanism with multiple molecular readouts in transfected cells plus in vivo confirmation, single lab\",\n      \"pmids\": [\"11212269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Central (intracerebroventricular) GLP-2 inhibits food intake in mice via GLP-2R expressed in multiple extrahypothalamic brain regions; disruption of GLP-1 receptor signaling (pharmacologically or genetically in GLP-1R-/- mice) potentiates the anorectic effect of GLP-2, indicating that GLP-1R signaling modulates CNS GLP-2 action.\",\n      \"method\": \"ICV injection in wild-type and GLP-1R-/- mice; exendin-(9-39) antagonist; LacZ transgenic reporter driven by GLP-2R promoter; GLP-2R expression mapping\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic and pharmacological epistasis in two independent mouse models, multiple orthogonal methods\",\n      \"pmids\": [\"11262390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The primary DPP-IV degradation product GLP-2(3-33) binds the GLP-2 receptor with ~7.5% affinity of GLP-2(1-33), stimulates cAMP at ~15% efficacy, and acts as a partial agonist/competitive antagonist at the GLP-2 receptor, attenuating the intestinotrophic effects of GLP-2(1-33) when co-administered at high doses.\",\n      \"method\": \"Receptor-binding assay and cAMP accumulation in cells expressing transfected human GLP-2R; in vivo intestinal growth assay in mice with co-administration\",\n      \"journal\": \"Regulatory peptides\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro receptor binding and functional cAMP assay combined with in vivo dose-response, single lab with multiple methods\",\n      \"pmids\": [\"11738243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"GLP-2 stimulates colonic growth via keratinocyte growth factor (KGF) released from subepithelial myofibroblasts that express the GLP-2 receptor; anti-KGF antibody abolishes GLP-2-induced large intestinal growth but not small intestinal growth, establishing KGF as an obligate downstream paracrine mediator in the colon.\",\n      \"method\": \"Immunohistochemistry and in situ hybridization for GLP-2R on myofibroblasts; double-labeling for alpha-smooth muscle actin and KGF; in vivo GLP-2 ± KGF antibody infusion in mice\",\n      \"journal\": \"Regulatory peptides\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — co-localization plus antibody neutralization epistasis in vivo, orthogonal methods, multiple species\",\n      \"pmids\": [\"15544847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"GLP-2R protein co-localizes with serotonin in enteroendocrine cells and with eNOS-expressing/VIP-positive enteric neurons in porcine intestine; GLP-2 infusion dose-dependently stimulates intestinal blood flow and upregulates intestinal eNOS mRNA, protein, and phosphorylation (eNOS-Ser1117), demonstrating that GLP-2 increases mesenteric blood flow via vasoactive neurotransmitters co-localized with GLP-2R.\",\n      \"method\": \"qRT-PCR on laser-capture microdissected subtissue, FISH, triple immunostaining/confocal microscopy; in vivo GLP-2 infusion in neonatal pigs with superior mesenteric artery blood flow measurement and eNOS quantification\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal localization methods combined with functional vascular endpoint, validated antibody, porcine model\",\n      \"pmids\": [\"16401478\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"GLP-2 rapidly activates divergent intracellular signaling pathways in neonatal piglet intestinal epithelial cells: within 1–4 h, GLP-2 phosphorylates PKA, PKB/Akt, ERK1/2, CREB, and c-Fos, suppresses caspase-3 activation, and upregulates Bcl-2 and IAP family members (XIAP, cIAP-2), preceding the trophic morphological changes seen at 48 h.\",\n      \"method\": \"In vivo GLP-2 infusion in TPN-fed neonatal piglets with intestinal tissue analysis by Western blotting, immunostaining for signaling proteins; BrdU proliferation and TUNEL apoptosis assays at multiple time points\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic time-course with multiple orthogonal molecular endpoints in a defined in vivo model, single lab\",\n      \"pmids\": [\"16954336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ErbB receptor signaling is required for the proliferative and bowel-growth effects of GLP-2: exogenous GLP-2 rapidly induces amphiregulin, epiregulin, and HB-EGF (ErbB ligands) and immediate-early gene expression in the gut in a GLP-2R-dependent manner (absent in Glp2r-/- mice), and these effects and the stimulatory actions on crypt cell proliferation are abolished by the pan-ErbB inhibitor CI-1033 or markedly diminished in hypomorphic Egfr(wa2) mice.\",\n      \"method\": \"Gene expression profiling, GLP-2 administration in wild-type, Glp2r-/- and Egfr(wa2) mice; pan-ErbB inhibitor CI-1033; metalloproteinase inhibitor; crypt cell proliferation assay\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic (two KO models) and pharmacological epistasis with multiple downstream readouts, single lab with orthogonal approaches\",\n      \"pmids\": [\"19523469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"GLP-2 potentiates L-type voltage-gated Ca2+ channel (VGCC) activity in hippocampal neurons through a PKA-dependent mechanism, and this potentiation partially mediates GLP-2-stimulated glucose uptake by primary hippocampal neurons. GLP-2(1-33) binds specifically to hippocampal neurons with Kd = 0.48 nM.\",\n      \"method\": \"Whole-cell patch clamp recording of barium currents; PKA inhibitor (PKI(14-22)); nifedipine for L-type Ca2+ channel block; [3H]-2-deoxyglucose uptake; 125I-labeled GLP-2 binding; fluorescent glucose analog imaging\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — patch clamp (gold standard for channel function) combined with pharmacological dissection and radioligand binding, single lab with multiple methods\",\n      \"pmids\": [\"19920220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"GLP-2R in POMC neurons suppresses food intake and gastric emptying; GLP-2-mediated anorectic and motility effects require MC4R signaling, as these effects were abolished in MC4R KO mice. Mice lacking Glp2r specifically in POMC neurons showed hyperphagia, accelerated gastric emptying, and late-onset obesity.\",\n      \"method\": \"Cre-LoxP conditional knockout (POMC-specific Glp2r deletion); ICV GLP-2 infusion; MC4R KO mice; 13C-octanoic acid breath test for gastric emptying; food intake measurement\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional genetic knockout with ICV pharmacology and epistasis via MC4R KO, multiple phenotypic readouts\",\n      \"pmids\": [\"22829581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Central GLP-2 enhances hepatic insulin sensitivity through PI3K signaling in POMC neurons: GLP-2R activation in POMC neurons initiates GLP-2R–p85α interaction, facilitating PI3K–Akt-dependent FoxO1 nuclear exclusion, modulating membrane excitability, and suppressing hepatic glucose production (HGP). Mice lacking GLP-2R in POMC neurons show glucose intolerance and hepatic insulin resistance.\",\n      \"method\": \"Conditional knockout (POMC-specific Glp2r-/- and POMC-p110α KO); Co-IP (GLP-2R–p85α); patch clamp for POMC neuron excitability; hyperinsulinemic-euglycemic clamp; FoxO1 nuclear/cytoplasmic fractionation; gluconeogenesis assay\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — Co-IP of receptor-PI3K interaction, patch clamp electrophysiology, and genetic epistasis via two independent KO lines, multiple orthogonal methods\",\n      \"pmids\": [\"23823479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"GLP-2R is expressed on both excitatory (substance P/ChAT-positive) and inhibitory (VIP/nNOS-positive) myenteric and submucosal neurons in mouse duodenum; GLP-2 inhibits smooth muscle contractility by decreasing cholinergic neurotransmission and increasing nitric oxide production, likely via ICC-DMP recruitment.\",\n      \"method\": \"Immunohistochemistry for GLP-2R co-localization with neuronal markers; in vitro contractility assay of intestinal smooth muscle; nitric oxide pathway pharmacology\",\n      \"journal\": \"Neurogastroenterology and motility\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-localization with functional contractility assay in vitro, single lab with two orthogonal methods\",\n      \"pmids\": [\"21752156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GLP-2R signaling controls circulating bile acid levels and relative bile acid species proportions in Gcgr-/- mice (loss of Glp2r in Gcgr-/- background lowers bile acids), and is required for small bowel growth in Gcgr-/- mice; however, GLP-2R is dispensable for glucose homeostasis in Gcgr-/- mice and for metabolic improvements after vertical sleeve gastrectomy.\",\n      \"method\": \"Double-knockout mice (Gcgr-/-:Glp2r-/-; Gcgr-/-:Gpbar1-/-); Glp2r-/- mice + VSG surgery; bile acid profiling; glucose tolerance testing; intestinal mass measurement\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with multiple double-KO lines and bariatric surgery model, multiple metabolic endpoints, single lab with rigorous controls\",\n      \"pmids\": [\"29937214\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Distal gut Gcg+ endocrine cells are the primary source of GLP-1 secreted in response to GPR119 agonism (AR231453), MC4R agonism (LY2112688), and LPS/TLR activation, as well as the acute GLP-1 response to metformin; in contrast, proximal gut Gcg+ cells are the main source for nutrient-stimulated (olive oil, arginine) GLP-1 secretion.\",\n      \"method\": \"Intestine-selective Gcg knockdown mice (GcgGut-/- and GcgDistalGut-/-); plasma GLP-1 measurement after administration of diverse secretagogues; glucose measurement\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two complementary segment-specific genetic reduction models with multiple pharmacologically distinct secretagogues, rigorous epistatic design\",\n      \"pmids\": [\"32278655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The proliferative effects of GLP-2 in the intestine are partially dependent on the intestinal epithelial IGF-1 receptor (IE-IGF-1R): IE-IGF-1R KO mice show diminished crypt cell proliferative responses to GLP-2 alone or with EGF, while small intestinal weight and crypt-villus height increases are preserved, indicating that GLP-2 acts through EGF and IGF-1R pathways for its proliferative but not its trophic effects.\",\n      \"method\": \"IE-IGF-1R conditional KO mice treated with GLP-2 and/or EGF; intestinal organoid cultures with EGF/IGF-1 treatment; intestinal growth parameter measurement; crypt cell proliferation assay\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO plus organoid reconstitution experiments with multiple growth endpoints, single lab with two orthogonal model systems\",\n      \"pmids\": [\"32147716\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"The human glucagon gene (GCG) was mapped to chromosome segment 2q36–37 by in situ hybridization using a 3H-labeled bovine glucagon cDNA probe.\",\n      \"method\": \"Radioactive in situ hybridization to human metaphase chromosomes\",\n      \"journal\": \"Cytogenetics and cell genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct chromosomal localization experiment, single lab, single method\",\n      \"pmids\": [\"6546710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A Gcg CreERT2 knockin mouse was generated by inserting CreERT2 into the endogenous Gcg locus; tamoxifen-induced recombination labeled 94–97% of pancreatic alpha cells, all known proglucagon-producing cell types (L cells, GLP-1-producing neurons), and revealed a glucagon/PP bihormonal cell population (~14–25% of PP+ cells). Intestinal L cells undergo rapid turnover (~half replaced within 2 weeks), whereas alpha cells and GLP-1 neurons persist for ≥5 months post-tamoxifen.\",\n      \"method\": \"Homologous recombination knockin; Cre-LoxP with Rosa26-tdTomato reporter; immunohistochemistry for cell-type markers; plasma glucagon, GLP-1 measurement\",\n      \"journal\": \"Diabetologia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockin with reporter validation across multiple cell types and temporal analysis, multiple orthogonal markers\",\n      \"pmids\": [\"28884202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GLP-2 dysregulates hepatic lipoprotein metabolism: exogenous GLP-2 administration increases fasting dyslipidemia, hepatic VLDL production, de novo lipogenesis gene expression, and hepatic lipid accumulation in hamsters and mice. Conversely, Glp2r-/- mice show reduced VLDL secretion and microsomal transfer protein activity with exacerbated hepatic lipid accumulation, indicating that GLP-2R signaling is required for normal hepatic lipid/lipoprotein homeostasis.\",\n      \"method\": \"IP GLP-2 administration in hamsters and C57BL/6J mice; Glp2r-/- mice on HFD; VLDL production assay; hepatic gene expression (lipogenesis genes); MTP lipid transfer activity; liver lipid quantification\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pharmacological gain-of-function plus genetic loss-of-function in two species with multiple mechanistic endpoints, single lab\",\n      \"pmids\": [\"30052880\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The GLP-2 antiresorptive effect on bone depends on PTH and is likely mediated through GLP-2R expressed in the parathyroid gland, whereas GIP acts directly on bone via GIPR expressed in osteoblasts and osteoclasts independent of PTH. GLP-2R was absent or only weakly expressed in osteoclasts.\",\n      \"method\": \"Randomized crossover clinical study in hypoparathyroidism patients; subcutaneous GIP and GLP-2 injections; bone turnover markers; GLP-2R and GIPR expression in human osteoblasts, osteoclasts, and parathyroid tissue\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — human clinical epistasis (PTH-deficient patients) combined with receptor expression in relevant cell types, single study\",\n      \"pmids\": [\"33852173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"GLP-2R activation is coupled to increased adenylate cyclase activity; the GLP-2R is expressed in a highly tissue-specific manner predominantly in the gastrointestinal tract (as established by studies of the cloned GLP-2 receptor).\",\n      \"method\": \"Cloned GLP-2R expressed in heterologous cells; adenylate cyclase/cAMP assay; tissue-specific expression analysis\",\n      \"journal\": \"Regulatory peptides\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor cloning with functional cAMP coupling assay and tissue expression, review summarizing multiple prior experiments\",\n      \"pmids\": [\"10828489\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GCG (proglucagon) encodes GLP-1, GLP-2, glucagon, and related peptides that are differentially processed in pancreatic alpha cells versus intestinal L cells and brainstem neurons; GLP-2, the best-characterized intestinal product, signals through a G protein-coupled GLP-2 receptor (primarily on subepithelial myofibroblasts and enteric neurons rather than directly on epithelial cells) to activate cAMP/PKA, PI3K/Akt, and ErbB signaling cascades, promoting intestinal growth via paracrine KGF and ErbB ligand release, suppressing epithelial apoptosis via Bcl-2/caspase pathways, increasing mesenteric blood flow via eNOS activation, modulating hepatic lipid metabolism and bile acid levels, and in the CNS acting on POMC neuron GLP-2R to suppress food intake and enhance hepatic insulin sensitivity through PI3K–FoxO1 and MC4R-dependent pathways.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GCG encodes proglucagon, a precursor that is differentially processed in pancreatic alpha cells versus intestinal L cells and proglucagon-producing neurons to yield glucagon, GLP-1, and GLP-2; intestinal L cells secrete GLP-1 and GLP-2 separately in response to luminal nutrients, distinct from the co-secretion of a larger GLP-containing peptide with glucagon from pancreas [#0, #18]. Segment-specific Gcg reduction establishes that distal-gut Gcg+ cells supply the GLP-1 evoked by GPR119, MC4R, TLR, and metformin stimulation, whereas proximal-gut cells supply nutrient-stimulated GLP-1 [#15]. The intestinotrophic product GLP-2 signals through the G protein-coupled GLP-2 receptor, which couples to adenylate cyclase and activates PKA-dependent transcriptional programs (AP-1, immediate-early genes) while engaging PKA-independent mitogenic mediators [#1, #21]. GLP-2R is expressed not on the proliferating epithelium itself but on subepithelial myofibroblasts, enteric neurons, and enteroendocrine cells, so its trophic action proceeds through paracrine intermediates: KGF release from myofibroblasts drives colonic growth, and ErbB ligands (amphiregulin, epiregulin, HB-EGF) acting through EGFR/ErbB and intestinal IGF-1R mediate crypt cell proliferation [#2, #6, #9, #16]. GLP-2 concurrently suppresses crypt cell apoptosis by inhibiting caspase-8/-3 activation and PARP cleavage and by upregulating Bcl-2 and IAP proteins, and it raises mesenteric blood flow via eNOS activation in VIP/NO enteric neurons [#3, #7, #8]. Beyond the gut, GLP-2R signaling regulates intestinal motility through cholinergic and nitrergic neurons [#13], hepatic lipoprotein and bile acid homeostasis [#14, #19], bone resorption via a PTH-dependent parathyroid mechanism [#20], and—through POMC neuron GLP-2R—suppresses food intake and gastric emptying via MC4R and enhances hepatic insulin sensitivity through a GLP-2R–p85\\u03b1/PI3K–Akt–FoxO1 axis [#11, #12]. The DPP-IV cleavage product GLP-2(3-33) acts as a partial agonist/competitive antagonist at the receptor [#5].\",\n  \"teleology\": [\n    {\n      \"year\": 1986,\n      \"claim\": \"Established that proglucagon products are processed and secreted differently by tissue, resolving how one gene yields distinct intestinal versus pancreatic peptides.\",\n      \"evidence\": \"RIA, HPLC on isolated perfused pig pancreas and ileum\",\n      \"pmids\": [\"3530719\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the processing enzymes responsible for tissue-specific cleavage\", \"Functional roles of secreted GLP-1/GLP-2 not addressed\"]\n    },\n    {\n      \"year\": 1984,\n      \"claim\": \"Localized the human GCG gene to a chromosomal locus, providing the genomic anchor for the proglucagon gene.\",\n      \"evidence\": \"Radioactive in situ hybridization to human metaphase chromosomes\",\n      \"pmids\": [\"6546710\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single method, single lab\", \"No functional or regulatory information about the locus\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Defined the GLP-2 receptor as a cAMP/PKA-coupled GPCR and showed that mitogenic signaling involves PKA-independent mediators, separating second-messenger generation from growth output.\",\n      \"evidence\": \"Transfected BHK cells expressing rat GLP-2R; cAMP, luciferase reporters, dominant-negative PKA, immunoblotting\",\n      \"pmids\": [\"10521425\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Heterologous cell system, not native epithelium\", \"Identity of PKA-independent mitogenic mediators undefined\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Mapped GLP-2R expression to enteroendocrine cells, brain, and lung, raising the key insight that epithelial trophic effects must be indirect.\",\n      \"evidence\": \"Northern blot, RT-PCR, immunocytochemistry across rodent and human tissues; cloned receptor cAMP coupling\",\n      \"pmids\": [\"10982769\", \"10828489\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify which downstream mediators relay the signal to epithelium\", \"Cell-type resolution limited at this stage\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showed GLP-2R activation is anti-apoptotic and that central GLP-2 suppresses feeding, expanding the receptor's role to cell survival and CNS energy balance.\",\n      \"evidence\": \"Caspase/PARP assays in transfected cells with murine chemotherapy models; ICV injection in WT and GLP-1R-/- mice with antagonist and reporter\",\n      \"pmids\": [\"11212269\", \"11262390\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Anti-apoptotic mechanism in transfected cells not yet linked to specific epithelial pathway\", \"CNS GLP-2R-expressing neuronal populations not resolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Characterized the DPP-IV product GLP-2(3-33) as a partial agonist/competitive antagonist, defining a built-in regulatory brake on GLP-2 signaling.\",\n      \"evidence\": \"Receptor binding and cAMP in human GLP-2R cells; in vivo co-administration intestinal growth assay\",\n      \"pmids\": [\"11738243\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological concentrations achieving antagonism in vivo unclear\", \"No structural basis for partial agonism\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified KGF from subepithelial myofibroblasts as an obligate paracrine mediator of colonic GLP-2 trophic action, providing the first molecular intermediate for indirect epithelial growth.\",\n      \"evidence\": \"IHC/ISH for GLP-2R on myofibroblasts; anti-KGF neutralization in vivo in mice\",\n      \"pmids\": [\"15544847\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"KGF dependence does not explain small intestinal growth\", \"Other paracrine mediators not yet identified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrated that GLP-2 increases mesenteric blood flow via eNOS in enteric neurons and rapidly activates divergent pro-survival/pro-growth signaling in epithelium, connecting receptor activation to vascular and trophic physiology.\",\n      \"evidence\": \"qRT-PCR on LCM tissue, FISH, confocal triple immunostaining, blood flow measurement in neonatal pigs; in vivo GLP-2 infusion time-course in TPN-fed piglets\",\n      \"pmids\": [\"16401478\", \"16954336\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Epithelial signaling in piglets correlative as to which are GLP-2R-direct versus paracrine\", \"Single species per study\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Established ErbB ligand release and EGFR/ErbB signaling as required for GLP-2 proliferative and bowel-growth effects, and showed GLP-2 modulates VGCC in neurons, defining the dominant trophic effector and a neuronal action.\",\n      \"evidence\": \"Gene profiling and epistasis in WT, Glp2r-/-, Egfr(wa2) mice with pan-ErbB inhibitor; patch clamp and radioligand binding in hippocampal neurons\",\n      \"pmids\": [\"19523469\", \"19920220\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking GLP-2R to metalloproteinase-dependent ErbB ligand shedding incomplete\", \"Physiological role of neuronal VGCC potentiation unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Resolved GLP-2R expression on excitatory and inhibitory enteric neurons and its inhibition of smooth muscle contractility, linking the receptor to gut motility control.\",\n      \"evidence\": \"IHC co-localization with neuronal markers; in vitro intestinal smooth muscle contractility with NO pathway pharmacology\",\n      \"pmids\": [\"21752156\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"ICC-DMP involvement inferred not demonstrated\", \"Single lab, in vitro contractility only\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified POMC neuron GLP-2R as the substrate for central anorectic and gastric-emptying effects and showed MC4R-dependence, mapping the CNS circuit for GLP-2 action.\",\n      \"evidence\": \"POMC-specific Glp2r conditional KO, ICV GLP-2, MC4R KO epistasis, gastric emptying breath test\",\n      \"pmids\": [\"22829581\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Source of endogenous ligand reaching POMC neurons unclear\", \"Link between POMC GLP-2R and downstream melanocortin release not detailed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined a GLP-2R–p85\\u03b1/PI3K–Akt–FoxO1 axis in POMC neurons controlling hepatic glucose production, establishing a direct receptor–PI3K physical and functional link for central glucose regulation.\",\n      \"evidence\": \"POMC-specific Glp2r and p110\\u03b1 KO; Co-IP of GLP-2R–p85\\u03b1; patch clamp; hyperinsulinemic-euglycemic clamp; FoxO1 fractionation\",\n      \"pmids\": [\"23823479\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"GLP-2R–p85\\u03b1 interaction shown by Co-IP without structural detail\", \"Whether interaction is direct or scaffolded not resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Created a Gcg lineage-tracing tool that catalogued all proglucagon-producing cell types and their turnover, providing the cellular map underlying tissue-specific GCG biology.\",\n      \"evidence\": \"Gcg-CreERT2 knockin with tdTomato reporter, IHC marker analysis, plasma hormone measurement\",\n      \"pmids\": [\"28884202\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not test functional consequences of cell turnover on peptide output\", \"Bihormonal glucagon/PP cell function unexplored\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed GLP-2R signaling governs hepatic lipoprotein metabolism and, in the Gcgr-/- background, controls bile acid levels and is required for small bowel growth while being dispensable for glucose homeostasis, distinguishing GLP-2R-dependent from -independent metabolic functions.\",\n      \"evidence\": \"VLDL/MTP assays and Glp2r-/- mice; double-KO mice (Gcgr-/-:Glp2r-/-, Gcgr-/-:Gpbar1-/-), VSG surgery, bile acid profiling\",\n      \"pmids\": [\"30052880\", \"29937214\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue site of GLP-2R action on hepatic lipid not localized\", \"Mechanism connecting GLP-2R to bile acid handling undefined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Pinpointed proximal versus distal Gcg+ cells as differential sources of secretagogue-specific GLP-1, and showed intestinal IGF-1R is required for GLP-2 proliferative but not trophic effects, refining both the source and effector arms of the pathway.\",\n      \"evidence\": \"Segment-specific Gcg knockdown mice with diverse secretagogues; IE-IGF-1R conditional KO and organoid reconstitution\",\n      \"pmids\": [\"32278655\", \"32147716\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How proliferative and trophic effects are mechanistically separated at the receptor level unclear\", \"Relative contributions of EGF versus IGF-1 axes not quantified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established that the GLP-2 antiresorptive bone effect is PTH-dependent via parathyroid GLP-2R, contrasting with the direct osteoblast/osteoclast action of GIP, defining an endocrine relay for skeletal regulation.\",\n      \"evidence\": \"Randomized crossover clinical study in hypoparathyroidism patients; bone turnover markers; receptor expression in human bone and parathyroid tissue\",\n      \"pmids\": [\"33852173\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single clinical study\", \"Direct demonstration of parathyroid GLP-2R signaling causing PTH change not shown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The proteases and regulatory inputs that route proglucagon toward glucagon versus GLP-1/GLP-2 in different cell types, and the structural basis of GLP-2R coupling to its divergent paracrine and PI3K effectors, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No timeline finding identifies the cell-specific proglucagon processing enzymes\", \"No structural model of GLP-2R or its p85\\u03b1 interaction\", \"Direct epithelial versus paracrine partitioning of GLP-2 effects incompletely quantified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 5, 15]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 15, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 12, 21]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [14, 19]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [6, 9, 16]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"GLP2R\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}